Y receptor agonist

Broqua P, Wettstein JG, Rocher MN, Gauthiermartin B, Junien JL (1995) Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6 215-222... 

PCSK9, proprotein convertase subtUisin/kexin type 9 PPAR-y, peroxisome-proliferator-activated receptor-y receptor agonists PPG, post-prandial... 

Pancrease pancreatin rizolipase. pancreatic polypeptide (PP) is an amidated peptide with a sequence that differs in human, rat, avian, frog and salmon forms. PP belongs to a family of peptides with a number of emerging members. Including neuropeptide Y (NPY) and peptide YY (PYY). These peptides appear to share a number of receptors. PP is a NEUROPEPTIDE Y RECEPTOR AGONIST. 

To date, the major treatments for NAFLD have been those aimed at lowering body weight and fat content. Loss of weight is often associated with decreased ALT values in one study, a 1% decrease in weight was associated with an 8% decrease in ALT activity. The association of NAFLD with insulin resistance has suggested treatment with antidiabetic medications, particularly those that increase insulin responsiveness (such as PPAR-y receptor agonists and metformin), but there are no conclusive studies that document safety and efficacy. 

FIGURE 5.10 Effects of co-expressed G-protein (G ) on neuropeptide NPY4 receptor responses (NPY-4). (a) Dose-response curves for NPY-4. Ordinates Xenopus laevis melanophore responses (increases light transmission). Ordinates logarithms of molar concentrations of neuropeptide Y peptide agonist PYY. Curves obtained after no co-transfection (labeled 0 jig) and co-transfection with cDNA for Gai6. Numbers next to the curves indicate jig of cDNA of Ga]g used for co-transfection, (b) Maximal response to neuropeptide Y (filled circles) and constitutive activity (open circles) as a function of pg cDNA of co-transfected G g. 

Zadina JE, Martiri Schild S, Gerall AA, et al Endomorphins novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density. Ann N Y... 

Choi Y, Chuang LF, Lam KM, Kung HF, Wang JM, Osburn BI, Chuang RY (1999) Inhibition of chemokine-induced chemotaxis of monkey leukocytes by mu-opioid receptor agonists. In Vivo 13 389-396... 

Kamei J, Saitoh A, Ohsawa M, Suzuki T, Misawa M, Nagase H, Kasuya Y. Antinociceptive effects of the selective non-peptidic delta-opioid receptor agonist TAN-67 in diabetic mice. Eur J Pharmacol 1995 276 131-135. 

Hong, Z. Y., Huang, Z. L., Qu, W. M. et al. (2005). An adenosine A receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats. J. Neurochem. 92 (6), 1542-9. 

The applicability of cinchonan carbamate CSPs for bioanalytical investigations using HPLC-ESI-MS/MS has been demonstrated by Fakt et al. [120]. The goal was the stereoselective bioanalysis of (R)-3-amino-2-fluoropropylphosphinic acid, a y-aminobutyric acid (GABA) receptor agonist, in blood plasma in order to determine whether this active enantiomer is in vivo converted to the 5-enantiomer. In this enantioselective HPLC-MS/MS bioassay, sample preparation consisted of... 

Chang Y, Covey DF, Weiss DS. 2000. Correlation of the apparent affinities and efficacies of Y-aminobutyric acidc receptor agonists. Mol Pharmacol 58 (6) 1375. 

Administration of levodopa plus carbidopa (or benserazide) remains the most effective treatment, but does not provide benefit beyond 3-5 y and is followed by gradual loss of symptom control, on-off fluctuations, and development of orobuccofacial and limb dyskinesias. These long-term drawbacks of levodopa therapy may be delayed by early monotherapy with dopamine receptor agonists. Treatment of advanced disease requires the combined administration of antiparkinsonian agents. 

The synthetic utility of this PKR process was exemplified in a formal total synthesis of the y-aminobutyric acid (GABA) receptor agonist (R)-baclofen [215],... 

Y. Matsumura, N. Mori, T. Nakano, H. Sasakura, T. Matsugi, H. Hara, Y. Morizawa, Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168 A novel 15-deoxy-15,15-difluoroprostaglandin p2 derivative. Tetrahedron Lett. 45 (2004) 1527-1529. 

---